Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

August 31, 2005

Conditions
AnemiaCancer
Interventions
DRUG

Aranesp®

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY